베트남의 경구 항당뇨병약 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the Vietnam oral anti-diabetic drug market size in 2026 is estimated at USD 168.7 million, growing from 2025 value of USD 162.46 million with 2031 projections showing USD 203.73 million, growing at 3.84% CAGR over 2026-2031.

This report is Segmented by Drug Class (Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, SGLT-2 Inhibitors, Others), Age Group (Adults, Pediatric, Geriatric), Diabetes Type (Type 1, Type 2), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

Vietnam Oral Anti-Diabetic Drug Market Trends and Insights

Rising Prevalence of Type-2 Diabetes

Vietnam's diabetes burden continues to intensify as urbanization and dietary change drive metabolic syndrome. Projections indicate a 21.1% relative rise in prevalence by 2045, making Vietnam one of the fastest-growing diabetes markets among middle-income countries . Gestational diabetes affects 22.8% of pregnancies, creating future demand for chronic therapy. Processed-food consumption raises average glycemic load in urban diets, especially among the expanding middle class. Earlier onset of disease lengthens lifetime drug use, and rice-fortification programs aimed at malnutrition may unintentionally sustain high glycemic intake. Together these factors underpin long-run demand in the Vietnam oral anti-diabetic drug market.

Expansion of National Health-Insurance Reimbursement

The amended Health Insurance Law effective July 2025 increases coverage to 100% for vulnerable groups and removes referral barriers, enabling direct specialist access. With 90% insurance penetration but 43% out-of-pocket spending, reimbursement expansion meaningfully lowers financial hurdles for modern therapies. Ho Chi Minh City's insurance authority is reviewing high-priced products with duplicative active ingredients, signaling tougher cost controls. Nevertheless, clearer reimbursement rules reduce uncertainty for investors and favor uptake of generics and value-added combinations across the Vietnam oral anti-diabetic drug market.

Safety & Side-Effect Profile of Certain OAD Classes

Polypharmacy affects 7.8% of older diabetes patients, heightening adverse-event risk. Fatal lactic acidosis from herbal products adulterated with undisclosed biguanides exposed regulatory gaps and raised public concern. Sulfonylurea-linked hypoglycemia remains a barrier in settings lacking immediate medical support. Resistance patterns in diabetic-foot infections underscore broader tolerability issues . Consequently, prescribers shift toward newer drugs with safer profiles, restraining expansion of legacy segments in the Vietnam oral anti-diabetic drug market.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Urban Middle-Class Healthcare Spending
2. Launch of Novel Fixed-Dose Combination OADs
3. Competitive Uptake of GLP-1 RAs & Insulin

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Biguanides held 38.42% of Vietnam oral anti-diabetic drug market share in 2025 due to metformin's entrenched first-line status. SGLT-2 inhibitors, supported by renal-cardio benefits, are forecast to post a 4.47% CAGR, making them the fastest riser. Sulfonylureas remain relevant for cost-sensitive patients, though hypoglycemia risks curb growth. DPP-4 inhibitors gain urban popularity for once-daily dosing. AstraZeneca's partnership with FPT Long Chau to broaden dapagliflozin counseling shows multinationals leveraging domestic chains. The segment's diversification demonstrates evolving therapeutic preferences within the Vietnam oral anti-diabetic drug market.

Early 2025 FDA approval of dapagliflozin for chronic kidney disease enlarges its addressable base, while domestic approvals of sitagliptin-metformin blends highlight growing local capability. Thiazolidinediones lose ground amid safety scrutiny, whereas meglitinides preserve a niche in flexible meal-time dosing. The "others" category, including next-generation combinations, signals further innovation potential as regulatory pathways streamline.

Adults commanded 68.31% revenue in 2025, yet the geriatric cohort posts the highest 4.54% CAGR, echoing Vietnam's transition toward an aging society. Polypharmacy and comorbidities require simplified regimens, spurring demand for fixed-dose combinations. Community screening programs by Merck Healthcare Vietnam and Long Chau underscore attention to older populations.

Herbal co-usage by 40.8% of patients complicates pharmacovigilance, reinforcing the need for education and monitoring. National EMR deployment by September 2025 will improve oversight and adherence, supporting growth in the Vietnam oral anti-diabetic drug market size for geriatric care.

Complete Report Scope:

• By Drug Class
  • Biguanides
  • Sulfonylureas
  • Meglitinides
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • SGLT-2 Inhibitors
  • Others
• By Age Group
  • Adults
  • Pediatric
  • Geriatric
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

1. Takeda Pharmaceuticals
2. Novo Nordisk
3. Pfizer
4. Eli Lilly and Company
5. Johnson & Johnson
6. Astellas Pharma
7. Boehringer Ingelheim
8. Merck
9. AstraZeneca
10. Bristol-Myers Squibb
11. Novartis
12. Sanofi
13. Daiichi-Sankyo
14. GlaxoSmithKline
15. Abbott Laboratories
16. DHG Pharma (Hau Giang)
17. Domesco
18. Traphaco
19. Mekophar
20. OPC Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Type-2 Diabetes
  • 4.2.2 Expansion Of National Health-Insurance Reimbursement
  • 4.2.3 Growing Urban Middle-Class Healthcare Spending
  • 4.2.4 Launch Of Novel Fixed-Dose Combination OADs
  • 4.2.5 Employer-Sponsored Diabetes Screening Programs
  • 4.2.6 Rice-Fortification Policy Sustaining Glycaemic Load
• 4.3 Market Restraints
  • 4.3.1 Safety & Side-Effect Profile of Certain OAD Classes
  • 4.3.2 Competitive Uptake Of GLP-1 Ras & Insulin
  • 4.3.3 MOH Price-Control Ceilings on Reimbursed Drugs
  • 4.3.4 Rising Use of Traditional Herbal Alternatives
• 4.4 Regulatory Landscape
• 4.5 Porters Five Forces Analysis
  • 4.5.1 Bargaining Power of Suppliers
  • 4.5.2 Bargaining Power of Consumers
  • 4.5.3 Threat of New Entrants
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Biguanides
  • 5.1.2 Sulfonylureas
  • 5.1.3 Meglitinides
  • 5.1.4 Thiazolidinediones
  • 5.1.5 Alpha-Glucosidase Inhibitors
  • 5.1.6 DPP-4 Inhibitors
  • 5.1.7 SGLT-2 Inhibitors
  • 5.1.8 Others
• 5.2 By Age Group
  • 5.2.1 Adults
  • 5.2.2 Pediatric
  • 5.2.3 Geriatric
• 5.3 By Diabetes Type
  • 5.3.1 Type 1 Diabetes
  • 5.3.2 Type 2 Diabetes
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Takeda
  • 6.3.2 Novo Nordisk
  • 6.3.3 Pfizer
  • 6.3.4 Eli Lilly
  • 6.3.5 Johnson & Johnson
  • 6.3.6 Astellas
  • 6.3.7 Boehringer Ingelheim
  • 6.3.8 Merck & Co.
  • 6.3.9 AstraZeneca
  • 6.3.10 Bristol Myers Squibb
  • 6.3.11 Novartis
  • 6.3.12 Sanofi
  • 6.3.13 Daiichi-Sankyo
  • 6.3.14 GSK
  • 6.3.15 Abbott
  • 6.3.16 DHG Pharma (Hau Giang)
  • 6.3.17 Domesco
  • 6.3.18 Traphaco
  • 6.3.19 Mekophar
  • 6.3.20 OPC Pharma

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment